NCT02283671View on ClinicalTrials.gov

Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

July 10, 2019

Study Completion Date

July 10, 2019

Conditions
Multiple SclerosisNeuromyelitis Optica
Interventions
BIOLOGICAL

Tolerogenic Dendritic cells loaded with myelin peptides

Somatic-cell therapy medicines application

Trial Locations (1)

08036

Hospital Clinic of Barcelona, Barcelona

All Listed Sponsors
lead

Sara Varea

OTHER

NCT02283671 - Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B | Biotech Hunter | Biotech Hunter